• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Disc Medicine Inc.

    8/15/25 7:16:36 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRON alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)


    DISC MEDICINE, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    254604101

    (CUSIP Number)


    Attention: Ommer Chohan, CFO
    Atlas Venture, 300 Technology Square, 8th Floor
    Cambridge, MA, 02139
    (857) 201-2700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    08/13/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Fund X, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,084,527.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,084,527.00
    11Aggregate amount beneficially owned by each reporting person

    1,084,527.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    ATLAS VENTURE ASSOCIATES X, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,084,527.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,084,527.00
    11Aggregate amount beneficially owned by each reporting person

    1,084,527.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Associates X, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,084,527.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,084,527.00
    11Aggregate amount beneficially owned by each reporting person

    1,084,527.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Fund XII, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    51,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    51,000.00
    11Aggregate amount beneficially owned by each reporting person

    51,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Associates XII, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    51,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    51,000.00
    11Aggregate amount beneficially owned by each reporting person

    51,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Associates XII, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    51,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    51,000.00
    11Aggregate amount beneficially owned by each reporting person

    51,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Opportunity Fund I, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    592,908.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    592,908.00
    11Aggregate amount beneficially owned by each reporting person

    592,908.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.7 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Associates Opportunity I, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    592,908.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    592,908.00
    11Aggregate amount beneficially owned by each reporting person

    592,908.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.7 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Associates Opportunity I, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    592,908.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    592,908.00
    11Aggregate amount beneficially owned by each reporting person

    592,908.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.7 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Opportunity Fund II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    420,549.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    420,549.00
    11Aggregate amount beneficially owned by each reporting person

    420,549.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.2 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Associates Opportunity II, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    420,549.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    420,549.00
    11Aggregate amount beneficially owned by each reporting person

    420,549.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.2 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    254604101


    1 Name of reporting person

    Atlas Venture Associates Opportunity II, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    420,549.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    420,549.00
    11Aggregate amount beneficially owned by each reporting person

    420,549.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.2 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    DISC MEDICINE, INC.
    (c)Address of Issuer's Principal Executive Offices:

    321 ARSENAL STREET, SUITE 101, WATERTOWN, MASSACHUSETTS , 02472.
    Item 1 Comment:
    This Amendment No. 4 to Schedule 13D ("Amendment No. 4") is being filed as an amendment to the statement on Schedule 13D relating to common stock, par value $0.0001 per share of Disc Medicine, Inc., a Delaware corporation, as filed with the Securities and Exchange Commission (the "SEC") on February 16, 2021 (the "Initial Schedule 13D") and later amended on February 14, 2023 ("Amendment No. 1") , September 21, 2023 ("Amendment No. 2") and January 24, 2024 ("Amendment No. 3" and together with the Initial Schedule 13D, Amendment No. 1 and Amendment No. 2 the "Prior Schedule 13D"). All capitalized terms not otherwise defined herein shall have the meanings ascribed to the terms in the Prior Schedule 13D. The Prior Schedule 13D is hereby amended and supplemented as follows and, except as expressly amended below, the Prior Schedule 13D remains in full force and effect.
    Item 5.Interest in Securities of the Issuer
    (a)
    As of the date hereof, Atlas X is the record owner of 1,084,527 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X. As of the date hereof, Atlas XII is the record owner of 51,000 shares of Common Stock. AVA XII LP is the general partner of Atlas XII and AVA XII LLC is the general partner of AVA XII LP. Each of Atlas XII, AVA XII LP and AVA XII LLC has shared voting and dispositive power over the shares held by Atlas XII. As such, each of Atlas XII, AVA XII LP and AVA XII LLC may be deemed to beneficially own the shares held by Atlas XII. As of the date hereof, AVOF is the record owner of 592,908 shares of Common Stock. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVOF, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVOF. As such, each of AVOF, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVOF. As of the date hereof, AVOF II is the record owner of 420,549 shares of Common Stock. AVAO II LP is the general partner of AVOF II and AVAO II LLC is the general partner of AVAO II LP. Each of AVOF II, AVAO II LP and AVAO II LLC has shared voting and dispositive power over the shares held by AVOF II. As such, each of AVOF II, AVAO II LP and AVAO II LLC may be deemed to beneficially own the shares held by AVOF II. Each of the Fund X Reporting Persons, Fund XII Reporting Persons, Opportunity Fund Reporting Persons and Opportunity Fund II Reporting Persons may be deemed to beneficially own 3.1%, 0.1%, 1.7% and 1.2%, respectively, of the Issuer's outstanding Common Stock, which percentages are calculated based upon 34,765,581 shares of Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30 on Form 10-Q, filed with the Securities and Exchange Commission on August 7, 2025. Collectively, the Reporting Persons beneficially own an aggregate of 2,148,984 shares of Common Stock, which represents an estimated 6.2% of the Issuer's outstanding Common Stock. The Fund X Reporting Persons, Fund XII Reporting Persons, Opportunity Fund Reporting Persons and the Opportunity Fund II Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes.
    (b)
    As of the date hereof, each of Atlas X, AVA X LP and AVA X LLC have shared voting power and shared dispositive power over 1,084,527 shares of Common Stock. As of the date hereof, each of Atlas XII, AVA XII LP and AVA XII LLC have shared voting power and shared dispositive power over 51,000 shares of Common Stock. As of the date hereof, each of AVOF, AVAO LP and AVAO LLC have shared voting power and shared dispositive power over 592,908 shares of Common Stock. As of the date hereof, each of AVOF II, AVAO II LP and AVAO II LLC have shared voting power and shared dispositive power over 420,549 shares of Common Stock.
    (c)
    The transactions in the common stock by the Reporting Persons during the past sixty days are set forth in Exhibit 99.1 and are incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Joint Filing Agreement

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Atlas Venture Fund X, L.P.
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates X, L.P., its general partner, By: Atlas Venture Associates X, LLC, its general partner, By Ommer Chohan, CFO
    Date:08/15/2025
     
    ATLAS VENTURE ASSOCIATES X, L.P.
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates X, LLC, its general partner, By Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Associates X, LLC
     
    Signature:/s/ Ommer Chohan
    Name/Title: Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Fund XII, L.P.
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates XII, L.P., its general partner, By: Atlas Venture Associates XII, LLC, its general partner, By Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Associates XII, L.P.
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates XII, LLC, its general partner, By Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Associates XII, LLC
     
    Signature:/s/ Ommer Chohan
    Name/Title:Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Opportunity Fund I, L.P.
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates Opportunity I, L.P., its GP, By: Atlas Venture Associates Opportunity I, LLC, its GP, By Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Associates Opportunity I, L.P.
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates Opportunity I, LLC, its GP, By Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Associates Opportunity I, LLC
     
    Signature:/s/ Ommer Chohan
    Name/Title:Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Opportunity Fund II, L.P.
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates Opportunity II, L.P., its GP, By: Atlas Venture Associates Opportunity II, LLC, its GP, By Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Associates Opportunity II, LP
     
    Signature:/s/ Ommer Chohan
    Name/Title:By: Atlas Venture Associates Opportunity II, LLC, its GP, By Ommer Chohan, CFO
    Date:08/15/2025
     
    Atlas Venture Associates Opportunity II, LLC
     
    Signature:/s/ Ommer Chohan
    Name/Title:Ommer Chohan, CFO
    Date:08/15/2025
    Get the next $IRON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRON

    DatePrice TargetRatingAnalyst
    7/21/2025$86.00Buy
    Truist
    7/3/2025$85.00Overweight
    Morgan Stanley
    6/11/2025$89.00Strong Buy
    Raymond James
    2/27/2025Buy
    TD Cowen
    11/5/2024$85.00Equal-Weight → Overweight
    Morgan Stanley
    11/4/2024$66.00 → $110.00Outperform → Strong Buy
    Raymond James
    10/23/2024$89.00Buy
    Jefferies
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $IRON
    SEC Filings

    View All

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/22/25 4:29:56 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/22/25 4:25:35 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Disc Medicine Inc.

    SCHEDULE 13D/A - Disc Medicine, Inc. (0001816736) (Subject)

    8/15/25 7:16:36 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Disc Medicine with a new price target

    Truist initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $86.00

    7/21/25 8:34:40 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Disc Medicine with a new price target

    Morgan Stanley resumed coverage of Disc Medicine with a rating of Overweight and set a new price target of $85.00

    7/3/25 8:01:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Disc Medicine with a new price target

    Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00

    6/11/25 7:53:18 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin sold $139,576 worth of shares (2,287 units at $61.03) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/26/25 6:01:57 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $1,966,286 worth of shares (32,174 units at $61.11) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/15/25 7:23:46 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $24,075 worth of shares (395 units at $60.95) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/7/25 5:00:08 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Leadership Updates

    Live Leadership Updates

    View All

    Disc Medicine Appoints Nadim Ahmed to its Board of Directors

    WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological

    7/14/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

    Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m

    11/12/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

    WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in

    10/23/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Financials

    Live finance-specific insights

    View All

    Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

    Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

    6/12/25 7:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

    Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

    5/14/25 9:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

    Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja

    1/21/25 7:45:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 8:00:05 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:27:54 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:19:39 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Disc Medicine to Participate in Upcoming Investor Conferences

    WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 3rd at 10:55 a.m. ET. 2025 Wells Fargo Healthcare Conference on Thursday, September 4th at 4:30 p.m. ET. H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th at 12:00 p.m. ET.Morgan Stanley 23rd Annual Global He

    8/27/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

    — Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming full exercise of common stock warrants, expected to fund planned operations into 2029 — — Industry expert Dan Baker, M.D., and OrbiMed representative Mona Ashiya, Ph.D., appointed to the Board of Directors — AUSTIN, TX and DURHAM, NC, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily rece

    8/26/25 6:30:00 AM ET
    $IRON
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

    Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meetingExpect initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) and multiple dose data from Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in Q4 2025Initiated Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expected in 2026Presented positive clinical data updates across the portfolio at the European Hematology Association (EHA) Annual Congress, including longer term efficacy and safety data from the

    8/7/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 4:33:10 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Disc Medicine Inc.

    SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

    11/8/24 10:52:39 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care